UC San Diego Health

Perceptyx Announces Winners of 2024 EX IMPACT Awards

Retrieved on: 
Thursday, April 4, 2024
RN, ESAB, Organization, Align Technology, Align, Talent management, Continual improvement process, Communication, EX, Partnership, Carhartt, Change management, Orthodontics, Intranet, UC, Acquisition, UC San Diego Health, Morale, Trust, Safety, Workforce, Workplace, Clarity, DEI, Nursing

TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.

Key Points: 
  • TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.
  • The EX IMPACT Awards recognize people-first organizations making a difference in workplace culture.
  • “The EX IMPACT Awards recognize organizations that use the Perceptyx People Insights Platform to improve their employees’ experience,” said Kirsten Helvey, Chief Customer Officer at Perceptyx.
  • “This EX Impact Award showcases the potential this type of strategy carries not only for our organization but others as well!”

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Retrieved on: 
Tuesday, April 9, 2024
AXL, Infection, Drug discovery, COVID-19, RNA-dependent RNA polymerase, FACP, FIDSA, RNA, Research, Publishing, AI, UC San Diego Health, Deep learning, GALILEO, Preprint, Orthornavirae, Therapy, Pandemic, BioRxiv, MAS, BRD4

LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.

Key Points: 
  • LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.
  • Using bioinformatics and deep learning, they also found MDL-001 to be a promising orally bioavailable broad-spectrum antiviral that blocks the RdRp Thumb-1 site.
  • In the second preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery" , Model Medicines details their foundational GALILEO AI platform and its core ChemPrint deep learning model for molecular property prediction.
  • By employing adaptive molecular embeddings and rigorous model training and validation methods, ChemPrint substantially outperformed conventional AI approaches.

MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence

Retrieved on: 
Thursday, February 22, 2024
OTCQB, Hospital, Kidney stone disease, Recurrence, AI, Kidney, Physician, Risk, UC, Patient, UC San Diego Health, Investment, Artificial intelligence, Cancer, Medical imaging

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is pleased to announce that the Limmi Disease Insights Platform is now being used in hospitals with an initial focus on kidney stone disease recurrence.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is pleased to announce that the Limmi Disease Insights Platform is now being used in hospitals with an initial focus on kidney stone disease recurrence.
  • UC San Diego Health is the first site that is utilizing Limmi’s Disease Insights Platform in a hospital setting.
  • Limmi's Disease Insights Platform has been meticulously designed to address the common challenges researchers face when dealing with large sets of data, particularly complex health data.
  • We have fortunately collected years of high quality kidney stone patient data to apply to Artificial Intelligence (AI).

AIXSCAN, INC. ARC60 Started Imaging Patients in the U.S.

Retrieved on: 
Thursday, February 22, 2024
Health, Medical Devices, Technology, Health Technology, Radiology, Clinical Trials, Artificial Intelligence, FDA, Stanford University, UC San Diego Health, Radiography, Patient, Medical imaging

The AIxSCAN, Inc. team is very pleased with the early ARC60 imaging results, both in terms of depiction of details and consistency of imaging quality.

Key Points: 
  • The AIxSCAN, Inc. team is very pleased with the early ARC60 imaging results, both in terms of depiction of details and consistency of imaging quality.
  • AIxSCAN, Inc. received additional seed funding in early September 2023 to support clinical trials and engineering projects.
  • AIxSCAN, Inc. is also in final discussions to partner with three more institutions as soon as additional ARC60 units come out of production.
  • Advisory Board member, is also very impressed with the ARC60 imaging platform capabilities.

Limmi appoints nationally recognized cancer researcher, Dr. Kader, to its Board of Directors

Retrieved on: 
Tuesday, March 5, 2024
Advisory board, Doctor of Philosophy, MD, Urinary diversion, Bladder cancer, FRCSC, Genomics, Risk, Patient, Big data, UC San Diego Health, Deep learning, UCSD, Prostate cancer, Pharmaceutical industry

"We're in a desperate need at this time for solutions like the one Limmi is offering.

Key Points: 
  • "We're in a desperate need at this time for solutions like the one Limmi is offering.
  • states Professor Kader , and continues, "As a surgeon scientist, I made a discovery regarding genetic risk in prostate cancer.
  • In addition to being a board-certified urologist who specializes in detecting, treating, and preventing prostate cancer, Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer.
  • He holds several patents for genetic discoveries related to early detection of prostate cancer.

Visage Launches Visage Ease VP™ for Apple Vision Pro

Retrieved on: 
Friday, February 2, 2024
Multimedia, SAN, EHR, Apple, UC San Diego Health, 2D, IPadOS, MacOS, UC, PME, Google Images, Health, Doctor of Philosophy, Eye, IOS, ASX

SAN DIEGO, Feb. 2, 2024 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced the launch of the groundbreaking Visage Ease VP for Apple Vision Pro, Apple's highly anticipated spatial computing platform released today.

Key Points: 
  • SAN DIEGO, Feb. 2, 2024 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced the launch of the groundbreaking Visage Ease VP for Apple Vision Pro, Apple's highly anticipated spatial computing platform released today.
  • Designed to take advantage of the unique capabilities of Apple Vision Pro, Visage Ease VP supports immersive, spatial experiences for diagnostic imaging and multimedia.
  • Visage Ease VP (visionOS) is the latest member of the Visage Ease family of native apps purpose-built for the Apple ecosystem, joining Visage Ease (iOS/iPadOS) and Visage Ease Pro™ (iPadOS).
  • Visage Ease VP is exclusively intended for use by Visage customers on the industry-leading Visage® 7 Enterprise Imaging Platform, version Visage 7.1.18h (or higher).

UC San Diego Health Receives 2023 Richard L. Doyle Award for Innovative Care Management Program

Retrieved on: 
Tuesday, January 23, 2024
Patient, Quality assurance, NCQA, Health, UC San Diego Health, SAN, UC, Documentation, Innovation, Transition, Epic, Patient satisfaction, Accreditation, National Committee, Organization, UCSD, MCG, Hearst Communications, EHR, Nursing

SAN DIEGO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- MCG Health, part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, has named UC San Diego Health a recipient of its 2023 Richard L. Doyle Award for Innovation and Leadership in Healthcare. The award is presented annually to two organizations — one payer and one provider — that use MCG solutions in exceptional ways to achieve improved patient care, reduce unnecessary costs, and optimize efficiency.

Key Points: 
  • SAN DIEGO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- MCG Health , part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, has named UC San Diego Health a recipient of its 2023 Richard L. Doyle Award for Innovation and Leadership in Healthcare .
  • - Parag Agnihotri, Chief Medical Officer, UC San Diego Health Population Health
    UC San Diego Health, an academic health system headquartered in San Diego, California, earned this prestigious award for seamlessly integrating evidence-based tools into its groundbreaking care management program.
  • UC San Diego Health Population Health utilizes this integrated approach to support prior authorizations, inpatient/surgical determinations, and level-of-care transition planning.
  • He added, "The UC San Diego Health Population Health leadership has demonstrated an innovative mindset with their approach to new technology and process redesign.

Limmi Disease Insights Platform to be used in university hospital setting to improve detection of kidney stone disease recurrence

Retrieved on: 
Tuesday, January 16, 2024
Kidney, Patient, Hospital, Artificial intelligence, UC, UC San Diego Health, Multimedia, AI, Cancer, Risk, Recurrence, Kidney stone disease, Physician

CARLSBAD, Calif., Jan. 16, 2024 /PRNewswire/ -- Limmi, a startup specializing in Artificial Intelligence and Data Insights for life sciences, today announced it will be using Limmi's disease insights platform in hospitals with an initial focus on kidney stone disease recurrence.

Key Points: 
  • CARLSBAD, Calif., Jan. 16, 2024 /PRNewswire/ -- Limmi, a startup specializing in Artificial Intelligence and Data Insights for life sciences, today announced it will be using Limmi's disease insights platform in hospitals with an initial focus on kidney stone disease recurrence.
  • Limmi's Disease Insights Platform has been meticulously designed to address the common challenges researchers face when dealing with large sets of data, particularly complex health data.
  • "We know that recurring kidney stones affect approximately 50% of patients—but we don't have a personalized risk predictor for individual patients.
  • We have fortunately collected years of high quality kidney stone patient data to apply to Artificial Intelligence (AI).

Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection

Retrieved on: 
Tuesday, December 5, 2023
Research, Medical Devices, Surgery, Genetics, Clinical Trials, Biotechnology, Managed Care, Health, Science, Oncology, Pancreatic cancer, Medical director, Disease, Risk, Patient, UC San Diego Health, Biology, Pancreas, PDAC, Survival rate, Master of Science, Exosome, Moores Cancer Center, University of Florida Health, Seminal vesicles, University, Diagnosis, Cancer, Pancreatitis, Doctor of Philosophy, Dana–Farber Cancer Institute, Pharmaceutical industry, MedStar Georgetown University Hospital, MD

Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
  • Known as a “silent killer,” approximately 80% of pancreatic cancer patients discover the disease in late stages when it has already spread and cannot be surgically removed.
  • “Currently, there is no standard early detection test for pancreatic cancer, resulting in an unmet need for innovative solutions to help solve this challenging disease,” said Harmeet Dhani, MD, MSc, Medical Director at Biological Dynamics and Principal Study Investigator.
  • “Collaborating with these cutting-edge institutions expands our work with some of the top cancer researchers in the world.

Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health

Retrieved on: 
Tuesday, November 14, 2023
Science, Women, Biotechnology, Research, Health, Baby, Maternity, Consumer, Clinical Trials, Disease, Reproductive Sciences, Risk, Mortality, Pregnancy, UC San Diego Health, Ochsner Health System, Pre-eclampsia, Blood, University, RNA, Birth control, Dietary supplement, Gynaecology, Ephraim Mirvis, Obstetrics

Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.

Key Points: 
  • Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.
  • “This monumental effort represents a new chapter for pregnancy health,” said Maneesh Jain, CEO and co-founder of Mirvie.
  • “Today, we face a massive crisis in maternal health, and innovative solutions are desperately needed.
  • The audacious scale of this generalizable study – involving over 10,000 individuals – creates the largest and richest biobank of pregnancy transcriptomes ever to exist.”
    Led by internationally renowned experts in pregnancy health, the U.S.-based study seeks to understand how RNA messages found in expectant mothers’ blood can predict life-threatening pregnancy complications.